These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 36478359)

  • 1. Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.
    Gokulakrishnan G; Kulkarni M; He S; Leeflang MM; Cabrera AG; Fernandes CJ; Pammi M
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD013129. PubMed ID: 36478359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review.
    Kulkarni M; Gokulakrishnan G; Price J; Fernandes CJ; Leeflang M; Pammi M
    Pediatrics; 2015 Feb; 135(2):e510-25. PubMed ID: 25601976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.
    Farombi-Oghuvbu I; Matthews T; Mayne PD; Guerin H; Corcoran JD
    Arch Dis Child Fetal Neonatal Ed; 2008 Jul; 93(4):F257-60. PubMed ID: 18218660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus.
    Harris SL; More K; Dixon B; Troughton R; Pemberton C; Horwood J; Ellis N; Austin N
    Eur J Pediatr; 2018 Apr; 177(4):521-532. PubMed ID: 29352349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial.
    Potsiurko S; Dobryanskyy D; Sekretar L
    BMC Pediatr; 2021 Jun; 21(1):286. PubMed ID: 34147090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(2):1-125. PubMed ID: 34055110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants.
    Nuntnarumit P; Khositseth A; Thanomsingh P
    J Perinatol; 2009 Feb; 29(2):137-42. PubMed ID: 19020527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Accuracy of Urinary N Terminal pro-B Type Natriuretic Peptides for Hemodynamically Significant-Patent Ductus Arteriosus in Preterm Infants.
    Hari Gopal S; Gokulakrishnan G; Kulkarni M; Fernandes CJ; Pammi M
    Neonatology; 2024; 121(1):1-6. PubMed ID: 37899032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates.
    Sanjeev S; Pettersen M; Lua J; Thomas R; Shankaran S; L'Ecuyer T
    J Perinatol; 2005 Nov; 25(11):709-13. PubMed ID: 16222347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of amino-terminal pro-brain natriuretic peptide as a predictive marker of symptomatic patent ductus arteriosus in preterm infants].
    Lu KS; Guo XL; Lv JF; Huang SL; Yang CH; Zou ZH; Chen ZJ; Lai CH; Yang BY
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1160-4. PubMed ID: 26575871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early NT-proBNP levels as a screening tool for the detection of hemodynamically significant patent ductus arteriosus during the first week of life in very low birth weight infants.
    Rodriguez-Blanco S; Oulego-Erroz I; Gautreaux-Minaya S; Perez-Muñuzuri A; Couce-Pico ML
    J Perinatol; 2018 Jul; 38(7):881-888. PubMed ID: 29785059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants.
    Nuntnarumit P; Chongkongkiat P; Khositseth A
    Acta Paediatr; 2011 Sep; 100(9):1217-21. PubMed ID: 21457304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal pro-brain natriuretic peptide used for screening hemodynamically significant patent ductus arteriosus in very low birth weight infants: How and when?
    Liu Y; Huang ZL; Gong L; Zhang Z; Zhang SC; Zhou YX
    Clin Hemorheol Microcirc; 2020; 75(3):335-347. PubMed ID: 32280084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NT-proBNP Levels Improve the Ability of Predicting a Hemodynamically Significant Patent Ductus Arteriosus in Very Low-Birth-Weight Infants.
    Buddhe S; Dhuper S; Kim R; Weichbrod L; Mahdi E; Shah N; Kona S; Sokal M
    J Clin Neonatol; 2012 Apr; 1(2):82-6. PubMed ID: 24027696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants.
    Choi BM; Lee KH; Eun BL; Yoo KH; Hong YS; Son CS; Lee JW
    Pediatrics; 2005 Mar; 115(3):e255-61. PubMed ID: 15687418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diseases associated with prematurity in correlation with N-terminal pro-brain natriuretic peptide levels during the early postnatal life.
    Fritz AS; Keller T; Kribs A; Hünseler C
    Eur J Pediatr; 2023 Jul; 182(7):3075-3082. PubMed ID: 37072630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?
    Lee JH; Shin JH; Park KH; Rhie YJ; Park MS; Choi BM
    Neonatology; 2013; 103(2):118-22. PubMed ID: 23182972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: A prospective observational study.
    Rodríguez-Blanco S; Oulego-Erroz I; Alonso-Quintela P; Terroba-Seara S; Jiménez-González A; Palau-Benavides M
    Pediatr Pulmonol; 2018 Aug; 53(8):1073-1081. PubMed ID: 29790673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.